US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CG Oncology Inc.

24.18

-0.9800-3.90%

Post-market: 24.180.00000.00%19:22 EDT

Volume:884.84K

Turnover:21.69M

Market Cap:1.84B

PE:-17.16

High:25.58

Open:24.21

Low:24.08

Close:25.16

Loading ...

Overview Company News Filings

CG Oncology Inc: Qtrly Shr Loss $0.46

THOMSON REUTERS

Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Buy Rating for CG Oncology: Promising Phase 3 Results and Strong Safety Profile of Cretostimogene

CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial

MT Newswires Live

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as Well as Consistent and Compelling Safety and Efficacy

THOMSON REUTERS

CG Oncology Inc -Median Duration of Response Exceeds 28 Months and Is Ongoing

THOMSON REUTERS

CG Oncology Inc - Announces 75.5% Complete Response Rate in Phase 3 Study

THOMSON REUTERS

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology Coverage Assumed by Morgan Stanley at Overweight

Buy Rating for CG Oncology: Promising Market Position and Upside Potential of Cretostimogene in NMIBC Treatment

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now?

Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts

CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62%

Simply Wall St.

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?

CG Oncology Amends Key Executive Employment Agreements

CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CGON/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGON","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":24.18,"timestamp":1747166400000,"preClose":25.16,"halted":0,"volume":884837,"hourTrading":{"tag":"盘后","latestPrice":24.18,"preClose":24.18,"latestTime":"19:22 EDT","volume":20728,"amount":501210.22,"timestamp":1747178550015},"delay":0,"floatShares":61123015,"shares":76221857,"eps":-1.408697,"marketStatus":"Closed","change":-0.98,"latestTime":"05-13 16:00:00 EDT","open":24.21,"high":25.58,"low":24.08,"amount":21686445.257564,"amplitude":0.059618,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.408697,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747209600000},"marketStatusCode":5,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":25.16,"preHourTrading":{"tag":"盘前","latestPrice":24.22,"preClose":25.16,"latestTime":"08:55 EDT","volume":38,"amount":910.3500399999999,"timestamp":1747140954605},"postHourTrading":{"tag":"盘后","latestPrice":24.18,"preClose":24.18,"latestTime":"19:22 EDT","volume":20728,"amount":501210.22,"timestamp":1747178550015},"volumeRatio":0.317662,"impliedVol":0.897,"impliedVolPercentile":0.844},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","floatShares":61123015,"roa":"-15.02%","roe":"-19.18%","lyrEps":-1.408697,"volumeRatio":0.317662,"shares":76221857,"dividePrice":0,"high":25.58,"amplitude":0.059618,"preClose":25.16,"low":24.08,"week52Low":14.8,"pbRate":"2.51","psRate":"1618.13","week52High":40.47,"institutionHeld":0,"latestPrice":24.18,"eps":-1.408697,"divideRate":0,"volume":884837,"delay":0,"ttmEps":-1.408697,"open":24.21,"prevYearClose":28.68,"prevWeekClose":23.74,"prevMonthClose":26.94,"prevQuarterClose":24.49,"fiveDayClose":21.7,"twentyDayClose":20.06,"sixtyDayClose":28.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGON\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522612522","title":"CG Oncology Inc: Qtrly Shr Loss $0.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2522612522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522612522?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:00","pubTimestamp":1743159601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA4MT7GL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2522430524","title":"Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522430524","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522430524?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":"- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin -Unresponsive Non-Muscle Invasive Bladder Cancer  -. - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Nave  and BCG-Exposed  NMIBC -. - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress -. IRVINE, Calif., March 28, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business updates.Any Time in High-Risk  BCG-Unresponsive NMIBC with carcinoma in situ. reached but exceeds 28 months as of the data cutoff of Januar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4139","CG","CGON","IE00BGHQF748.EUR","BCG","CR","US30Y.BOND","BK4196","BK4135","BK4225","US10Y.BOND","US5Y.BOND","LU1261432733.SGD","IE00B19Z3B42.SGD","US7Y.BOND","IE0002270589.USD","LU0868494617.USD","US2Y.BOND","CI","US6M.BOND","BK4161","BK4588","BK4203","LU0289739699.SGD","US3Y.BOND","US12M.BOND","IE00B3QW5Z07.USD","IE00B19Z3581.USD","IE00B64PRP62.GBP","LU1059921491.USD","HR","IE00BSNM7G36.USD","BK4585"],"gpt_icon":0},{"id":"2522304051","title":"CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304051?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:51","pubTimestamp":1742899860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 06:51 ET (10:51 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2522044344","title":"Buy Rating for CG Oncology: Promising Phase 3 Results and Strong Safety Profile of Cretostimogene","url":"https://stock-news.laohu8.com/highlight/detail?id=2522044344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522044344?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:16","pubTimestamp":1742897764,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) today and set a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-promising-phase-3-results-and-strong-safety-profile-of-cretostimogene?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-promising-phase-3-results-and-strong-safety-profile-of-cretostimogene?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","CG"],"gpt_icon":0},{"id":"2522777826","title":"CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522777826","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522777826?lang=en_us&edition=fundamental","pubTime":"2025-03-25 00:36","pubTimestamp":1742834172,"startTime":"0","endTime":"0","summary":"CG Oncology  rose over 4% on Monday after the company said roughly 76% of patients in a phase 3 trial of cretostimogene for high-risk bladder cancer showed a complete response at some point.As of Jan. 20, 46% of patients remained in complete response at 12 months, with 30 confirmed responses at 24 months.The study evaluated cretostimogene monotherapy for high-risk Bacillus Calmette Guerin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Data show that 83 out of 110 patients in the trial achieved complete response at some point.Data also showed that cretostimogene levels peaked immediately after administration and lasted locally for 4 to 5 days. There was no systemic exposure reported.These results were presented at the recent annual European Association of Urology Congress in Madrid, Spain.Price: 28.26, Change: +1.21, Percent Change: +4.47","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4135","CG","BK4139","CGON","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2521742270","title":"Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as Well as Consistent and Compelling Safety and Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521742270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521742270?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA9KM6Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2521479537","title":"CG Oncology Inc -Median Duration of Response Exceeds 28 Months and Is Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521479537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521479537?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA9KM6Z0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2521374764","title":"CG Oncology Inc - Announces 75.5% Complete Response Rate in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2521374764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521374764?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA9KM6Z0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2521747112","title":"Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747112","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747112?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post creto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047782/0/en/Cretostimogene-Grenadenorepvec-Data-Continues-to-Demonstrate-Best-in-Class-Durability-of-Response-as-well-as-Consistent-and-Compelling-Safety-and-Efficacy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CR","CGON","BK4139","BK4161","BCG"],"gpt_icon":0},{"id":"2517251456","title":"CG Oncology Coverage Assumed by Morgan Stanley at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2517251456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517251456?lang=en_us&edition=fundamental","pubTime":"2025-03-08 01:27","pubTimestamp":1741368420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 12:27 ET (17:27 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","CGON"],"gpt_icon":0},{"id":"2517484575","title":"Buy Rating for CG Oncology: Promising Market Position and Upside Potential of Cretostimogene in NMIBC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484575","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484575?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:19","pubTimestamp":1741349994,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. (CGON) has received a new Buy rating, initiated by Morgan Stanley analyst, Sean Laaman. Sean Laaman’s rating is based on the prom...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-promising-market-position-and-upside-potential-of-cretostimogene-in-nmibc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-promising-market-position-and-upside-potential-of-cretostimogene-in-nmibc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2514837053","title":"CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837053","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837053?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Feb.  26, 2025  (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032854/0/en/CG-Oncology-to-Present-at-the-TD-Cowen-45th-Annual-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TD","CGON","BK4207","BK4127","BK4566","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4135","COWN","BK4139","CG","BK4585","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2514018475","title":"Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018475","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514018475?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:49","pubTimestamp":1740494963,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where CG Oncology, Inc.  stands against the other oversold biotech stocks to buy now.Goldman Sachs clarified biotech as a frequently disregarded area of the investment world. John Flood, Head of Americas Equities Sales Trading at Goldman, wrote in a letter to clients that biotech equities offered an unnoticed opportunity for investors hoping to profit from the Fed’s recent rate decreases. Because biotech equities are sensitive to interest rate changes and frequently depend on anticipated future revenues, they are particularly impacted. The cost of capital has a significant effect on these equities as well. These equities have substantial upsid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-inc-cgon-oversold-144923366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","BK4135","PSQ","TSYW.SI","TQQQ","US7Y.BOND","BK4159","BK4150","BK4077","SQQQ","US10Y.BOND","CGON","US30Y.BOND","FOMC","US6M.BOND","QLD",".IXIC","MNQmain","US3Y.BOND","CG","US12M.BOND","USJW.SI","BK4139","US2Y.BOND","CAGR","US5Y.BOND","QID","IE00B64PRP62.GBP","NVIW.SI","USAW.SI","NQmain","IE00BGHQF748.EUR","RSI"],"gpt_icon":1},{"id":"2513506752","title":"Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2513506752","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513506752?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:29","pubTimestamp":1740335348,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where CG Oncology, Inc.  stands against the other oversold pharma stocks to buy according to analysts.On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity drugs. She believed the industry may not underperform this year, at least in the first half. However, there are still several questions surrounding the performance of obesity drugs, as major players in the domain have exhibited contrasting previous year performance.Angelica Peebles, CNBC’s Health and Pharma reporter, sat with Eli Lilly’s Chief Scientific Officer to talk about the weight loss sector. From the conversation, she reported that the domain poses opportunity for drugs that are easier to use, such as pills, and medicines that make people lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-cg-oncology-inc-cgon-182908860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","TQQQ","USAW.SI","IE00B3QW5Z07.USD","SQQQ",".IXIC","IE00BGHQF748.EUR","BK4139","CG","NQmain","MNQmain","USJW.SI","TSYW.SI","CGON","IE00B64PRP62.GBP","PSQ","NVIW.SI","QLD","QID"],"gpt_icon":1},{"id":"2508117475","title":"CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508117475","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508117475?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:05","pubTimestamp":1738584301,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, CG Oncology's stock price might be vulnerable to their trading decisions. A total of 12 investors have a majority stake in the company with 51% ownership. If you want to know who really controls CG Oncology, Inc. , then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 62% to be precise, is institutions. In other words, the group stands to gain the most  from their investment into the company.Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.NasdaqGS:CGON Earnings and Revenue Growth February 3rd 2025. While studying institutional ownership for a company can add value to your research, it is also a good practice to resear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-inc-nasdaq-cgon-120501999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","BK4585","USJW.SI","IE00B64PRP62.GBP","TSYW.SI","BK4588","BK4112","LU2095319765.USD","QID","NVIW.SI","NQmain","BK4135","MNQmain","IE00BKPKM429.USD","PSQ","CG","IE00B3QW5Z07.USD","NDAQ","USAW.SI","LU2210150020.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","SQQQ","CGON","QLD","TQQQ","BK4139"],"gpt_icon":1},{"id":"2508962291","title":"Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2508962291","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508962291?lang=en_us&edition=fundamental","pubTime":"2025-01-31 22:40","pubTimestamp":1738334407,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANI Pharmaceuticals  one of those stocks right now?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.ANI Pharmaceuticals is one of 1010 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 .ANI Pharmaceuticals, Inc.  : Free Stock Anal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-pharmaceuticals-anip-stock-outpacing-144007594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","ANIP","CGON"],"gpt_icon":0},{"id":"2504127299","title":"Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504127299","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504127299?lang=en_us&edition=fundamental","pubTime":"2025-01-16 22:55","pubTimestamp":1737039314,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc.  closed the last trading session at $29.61, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.13 indicates a 123.3% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $11.12. While the lowest estimate of $50 indicates a 68.9% increase from the current price level, the most optimistic analyst expects the stock to surge 180.3% to reach $83. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/does-cg-oncology-inc-cgon-145514578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CG","IE00B3QW5Z07.USD","CGON","IE00B64PRP62.GBP","BK4135","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2502848804","title":"CG Oncology Amends Key Executive Employment Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2502848804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502848804?lang=en_us&edition=fundamental","pubTime":"2025-01-11 05:49","pubTimestamp":1736545764,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. ( ($CGON) ) has provided an update. CG Oncology, Inc. has entered into amended and restated employment agreements with its top ex...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cg-oncology-amends-key-executive-employment-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cg-oncology-amends-key-executive-employment-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","BK4135","IE00B64PRP62.GBP","CGON"],"gpt_icon":0},{"id":"2502818959","title":"CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2502818959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502818959?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:08","pubTimestamp":1736532480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 10, 2025 13:08 ET (18:08 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2502447892","title":"Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2502447892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502447892?lang=en_us&edition=fundamental","pubTime":"2025-01-11 01:10","pubTimestamp":1736529013,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive top...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pfizer-study-impact-on-cg-oncology-to-be-minimal-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pfizer-study-impact-on-cg-oncology-to-be-minimal-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0225771236.USD","BK4599","BK4581","LU0985481810.HKD","BK4568","BK4534","PFE","CGON","IE00B3QW5Z07.USD","LU1066051498.USD","LU1066053197.SGD","LU0225284248.USD","LU1894683264.USD","LU0306806265.USD","SG9999002224.SGD","SG9999001176.SGD","BK4592","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999002232.USD","LU0289739699.SGD","SG9999001176.USD","BK4550","BK4007","LU0306807586.USD","CG","LU0321505868.SGD","IE00BLSP4452.SGD","LU0456855351.SGD","BK4588","LU0058720904.USD","LU1894683348.USD","IE0002270589.USD","IE00BBT3K403.USD","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505439.SGD","LU0868494617.USD","IE000M9KFDE8.USD","SG9999003800.SGD","SGXZ57979304.SGD","SG9999011175.SGD","IE00B64PRP62.GBP","BK4533","IE00BGHQF748.EUR","BK4139","BK4135","LU1883839398.USD","IE00BLSP4239.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGON\",params:#limit:5,,,undefined,":[{"date":"2025-05-13","symbol":"CGON","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747123200000,"name":null,"time":"Pre-Market","dateTimestamp":1747108800000,"actualEps":null},{"market":"US","date":"2025-03-28","symbol":"CGON","fiscalQuarterEnding":"2024/12","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2024-11-12","symbol":"CGON","fiscalQuarterEnding":"2024/09","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGON\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGON\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.8,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":10,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CGON\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CGON","date":"2025-05-12","current":-20.553469,"percent":0.934426,"low":-77.942097,"twenty":-49.99741,"median":-39.070966,"eighty":-28.006384,"high":-13.496527,"avg":-39.876482,"sd":14.138363,"marketCap":1809506885},"quantilePoints":[{"date":"2024-01-26","current":-62.124194,"twenty":-62.124194,"median":-62.124194,"eighty":-62.124194,"marketCap":2539823423},{"date":"2024-02-02","current":-61.712969,"twenty":-61.712969,"median":-60.379514,"eighty":-59.355029,"marketCap":2523011292},{"date":"2024-02-09","current":-63.452965,"twenty":-62.124194,"median":-60.590915,"eighty":-59.355029,"marketCap":2594147579},{"date":"2024-02-16","current":-77.177799,"twenty":-70.608092,"median":-61.918582,"eighty":-60.168112,"marketCap":3155259972},{"date":"2024-02-23","current":-75.080046,"twenty":-72.448911,"median":-64.672589,"eighty":-60.20714,"marketCap":3069497532},{"date":"2024-03-01","current":-72.705845,"twenty":-73.870179,"median":-70.608092,"eighty":-60.516111,"marketCap":2972433066},{"date":"2024-03-08","current":-64.818944,"twenty":-72.891228,"median":-69.827533,"eighty":-60.799064,"marketCap":2649992888},{"date":"2024-03-15","current":-60.493345,"twenty":-72.302556,"median":-67.469593,"eighty":-60.20714,"marketCap":2473149409},{"date":"2024-03-22","current":-66.867912,"twenty":-72.162706,"median":-65.355579,"eighty":-60.438055,"marketCap":2733760852},{"date":"2024-03-28","current":-56.207672,"twenty":-71.967566,"median":-64.762028,"eighty":-59.842879,"marketCap":2732086332},{"date":"2024-04-05","current":-51.752186,"twenty":-71.648838,"median":-63.50175,"eighty":-58.14191,"marketCap":2515518513},{"date":"2024-04-12","current":-54.631116,"twenty":-71.284577,"median":-62.382039,"eighty":-56.136384,"marketCap":2655454642},{"date":"2024-04-19","current":-48.420853,"twenty":-71.001624,"median":-61.712969,"eighty":-54.576279,"marketCap":2353592420},{"date":"2024-04-26","current":-49.627262,"twenty":-70.73168,"median":-60.54213,"eighty":-53.208102,"marketCap":2412232322},{"date":"2024-05-03","current":-54.151294,"twenty":-70.286112,"median":-60.183337,"eighty":-53.600185,"marketCap":2632131954},{"date":"2024-05-10","current":-35.176138,"twenty":-69.778748,"median":-59.371617,"eighty":-52.278619,"marketCap":2000537303},{"date":"2024-05-17","current":-36.289307,"twenty":-68.393255,"median":-58.232975,"eighty":-49.860318,"marketCap":2063845445},{"date":"2024-05-24","current":-35.140985,"twenty":-67.52163,"median":-57.330453,"eighty":-49.032283,"marketCap":1998538098},{"date":"2024-05-31","current":-40.179539,"twenty":-67.228921,"median":-56.207672,"eighty":-47.173317,"marketCap":2285090743},{"date":"2024-06-07","current":-40.894311,"twenty":-66.477632,"median":-55.878652,"eighty":-42.192617,"marketCap":2325741235},{"date":"2024-06-14","current":-40.788853,"twenty":-65.885708,"median":-55.522213,"eighty":-41.278647,"marketCap":2319743621},{"date":"2024-06-21","current":-37.625109,"twenty":-65.85969,"median":-54.631116,"eighty":-40.788853,"marketCap":2139815216},{"date":"2024-06-28","current":-35.445642,"twenty":-65.443392,"median":-54.494024,"eighty":-40.683395,"marketCap":2015864537},{"date":"2024-07-05","current":-36.125261,"twenty":-64.796178,"median":-54.151294,"eighty":-39.560851,"marketCap":2054515824},{"date":"2024-07-12","current":-40.378738,"twenty":-64.675841,"median":-53.136814,"eighty":-38.206301,"marketCap":2296419569},{"date":"2024-07-15","current":-41.491907,"twenty":-64.64657,"median":-52.780375,"eighty":-38.236766,"marketCap":2359727711},{"date":"2024-08-02","current":-39.652248,"twenty":-64.6173,"median":-52.752957,"eighty":-38.267232,"marketCap":2255102676},{"date":"2024-08-09","current":-38.949194,"twenty":-63.924553,"median":-51.752186,"eighty":-38.000071,"marketCap":2215118586},{"date":"2024-08-16","current":-40.572681,"twenty":-63.472479,"median":-49.956283,"eighty":-38.105529,"marketCap":2307449488},{"date":"2024-08-23","current":-42.377221,"twenty":-62.965116,"median":-49.723226,"eighty":-38.189896,"marketCap":2410077328},{"date":"2024-08-30","current":-43.2618,"twenty":-62.33047,"median":-48.934948,"eighty":-38.276606,"marketCap":2460385093},{"date":"2024-09-06","current":-44.299706,"twenty":-62.063778,"median":-48.270052,"eighty":-38.375033,"marketCap":2519412871},{"date":"2024-09-13","current":-41.079839,"twenty":-61.869081,"median":-45.980618,"eighty":-38.588613,"marketCap":2336292606},{"date":"2024-09-20","current":-46.127835,"twenty":-61.368222,"median":-44.806865,"eighty":-38.861791,"marketCap":2623382252},{"date":"2024-09-27","current":-43.379744,"twenty":-60.747027,"median":-44.736098,"eighty":-39.046612,"marketCap":2467092795},{"date":"2024-10-04","current":-42.412604,"twenty":-60.551887,"median":-44.517902,"eighty":-39.324835,"marketCap":2412089639},{"date":"2024-10-11","current":-40.667036,"twenty":-60.382766,"median":-44.458898,"eighty":-39.52313,"marketCap":2312815649},{"date":"2024-10-18","current":-43.356155,"twenty":-60.203473,"median":-44.063818,"eighty":-39.574912,"marketCap":2465751255},{"date":"2024-10-25","current":-42.990529,"twenty":-60.177247,"median":-43.698192,"eighty":-39.657154,"marketCap":2444957379},{"date":"2024-10-31","current":-42.837202,"twenty":-60.01213,"median":-43.662809,"eighty":-39.673778,"marketCap":2436237366},{"date":"2024-11-08","current":-46.068863,"twenty":-59.381569,"median":-43.651015,"eighty":-39.804577,"marketCap":2620028401},{"date":"2024-11-15","current":-32.980568,"twenty":-59.208121,"median":-43.63922,"eighty":-39.654701,"marketCap":2400853462},{"date":"2024-11-22","current":-30.044833,"twenty":-58.542987,"median":-43.538968,"eighty":-38.997903,"marketCap":2187143689},{"date":"2024-11-29","current":-32.283796,"twenty":-58.232975,"median":-43.444613,"eighty":-38.328163,"marketCap":2350131206},{"date":"2024-12-06","current":-31.17825,"twenty":-58.005312,"median":-43.379744,"eighty":-38.000071,"marketCap":2269651893},{"date":"2024-12-13","current":-26.821099,"twenty":-57.745125,"median":-43.279491,"eighty":-37.543086,"marketCap":1952468717},{"date":"2024-12-20","current":-26.031423,"twenty":-56.915781,"median":-43.120267,"eighty":-36.394765,"marketCap":1894983493},{"date":"2024-12-27","current":-27.044066,"twenty":-56.349294,"median":-43.061296,"eighty":-36.125261,"marketCap":1968699839},{"date":"2025-01-03","current":-26.914002,"twenty":-56.207672,"median":-43.037707,"eighty":-35.33784,"marketCap":1959231684},{"date":"2025-01-10","current":-28.298257,"twenty":-56.136384,"median":-42.978735,"eighty":-34.953504,"marketCap":2059999900},{"date":"2025-01-17","current":-27.034776,"twenty":-55.969133,"median":-42.872585,"eighty":-33.374909,"marketCap":1968023542},{"date":"2025-01-24","current":-32.158189,"twenty":-55.840266,"median":-42.689773,"eighty":-32.852839,"marketCap":2340987506},{"date":"2025-01-31","current":-31.530712,"twenty":-55.653821,"median":-42.565931,"eighty":-32.283796,"marketCap":2295309701},{"date":"2025-02-07","current":-31.405216,"twenty":-55.437216,"median":-42.394913,"eighty":-32.036945,"marketCap":2286174140},{"date":"2025-02-14","current":-29.805151,"twenty":-55.004006,"median":-42.206678,"eighty":-31.677123,"marketCap":2169695737},{"date":"2025-02-21","current":-29.512328,"twenty":-54.631116,"median":-41.999801,"eighty":-31.530712,"marketCap":2148379428},{"date":"2025-02-28","current":-25.768383,"twenty":-54.494024,"median":-41.775708,"eighty":-31.373843,"marketCap":1875835192},{"date":"2025-03-07","current":-28.226,"twenty":-54.39406,"median":-41.609082,"eighty":-31.094637,"marketCap":2054739928},{"date":"2025-03-14","current":-27.138374,"twenty":-54.151294,"median":-41.292708,"eighty":-30.560445,"marketCap":1975565066},{"date":"2025-03-21","current":-29.020804,"twenty":-53.671473,"median":-41.068045,"eighty":-30.21301,"marketCap":2112598481},{"date":"2025-03-28","current":-28.173711,"twenty":-53.493253,"median":-40.922206,"eighty":-29.826066,"marketCap":2050933444},{"date":"2025-04-04","current":-16.223536,"twenty":-52.780375,"median":-40.788853,"eighty":-29.478125,"marketCap":1428303862},{"date":"2025-04-11","current":-15.26259,"twenty":-52.725539,"median":-40.592885,"eighty":-29.073094,"marketCap":1343703153},{"date":"2025-04-17","current":-17.504797,"twenty":-52.648767,"median":-40.36956,"eighty":-28.807616,"marketCap":1541104808},{"date":"2025-04-25","current":-18.630229,"twenty":-51.927664,"median":-39.710836,"eighty":-28.715432,"marketCap":1640186719},{"date":"2025-05-02","current":-24.014988,"twenty":-51.631545,"median":-39.587801,"eighty":-28.276198,"marketCap":2114255557},{"date":"2025-05-09","current":-20.891121,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"marketCap":1839233409},{"date":"2025-05-12","current":-20.553469,"twenty":-49.99741,"median":-39.070966,"eighty":-28.006384,"marketCap":1809506885}],"updateTime":1747193582913}}}